{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:57:55Z","timestamp":1787068675310,"version":"build-2736575974"},"reference-count":97,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T00:00:00Z","timestamp":1655251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81730085"],"award-info":[{"award-number":["81730085"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81803128"],"award-info":[{"award-number":["81803128"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81974475"],"award-info":[{"award-number":["81974475"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["Shanghai Sailing Program 18YF1414200"],"award-info":[{"award-number":["Shanghai Sailing Program 18YF1414200"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Pemphigus is a chronic and severe autoimmune bullous disease caused by autoantibodies targeting adhesion molecules between keratinocytes. It requires 2\u20133 years on average to manage the disease. To date, although Rituximab combined with short-term systemic glucocorticoids was accepted as first-line therapy, systemic glucocorticoids remain the primary therapeutic option for pemphigus patients, successfully decreasing morbidity and mortality from pemphigus. However, novel therapeutic strategies are desirable due to the low efficacy in some subset of patients and the long-term severe adverse effects of traditional therapies. Recently, immunotherapy has proved to be encouraging for disease control or cure. Based on the current understanding of the immune mechanisms of pemphigus, we review the immune targets and corresponding agents applied in practice or under clinical trials. The goals of the novel treatments are to improve the quality of life of pemphigus patients by improving efficacy and safety, minimizing side effects, achieving fast disease control, or curing the disease.<\/jats:p>","DOI":"10.3389\/fmed.2022.901239","type":"journal-article","created":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T03:31:48Z","timestamp":1655263908000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Immunotherapy for Pemphigus: Present and Future"],"prefix":"10.3389","volume":"9","author":[{"given":"Huijie","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuming","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.jid.2019.11.005","article-title":"Recent advances in understanding pemphigus and bullous pemphigoid","volume":"140","author":"Hammers","year":"2020","journal-title":"J Invest Dermatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S0190-9622(99)70183-0","article-title":"The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile","volume":"40","author":"Amagai","year":"1999","journal-title":"J Am Acad Dermatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e92021","DOI":"10.1172\/jci.insight.92021","article-title":"Setting the target for pemphigus vulgaris therapy","volume":"2","author":"Ellebrecht","year":"2017","journal-title":"JCI Insight."},{"key":"B4","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.rmed.2009.01.003","article-title":"The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use","volume":"103","author":"Manson","year":"2009","journal-title":"Respir Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1080\/1744666X.2020.1672535","article-title":"Treatment of pemphigus vulgaris: part 1 - current therapies","volume":"15","author":"Yanovsky","year":"2019","journal-title":"Expert Rev Clin Immunol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1111\/j.1365-2133.2003.05665.x","article-title":"British Association of, Guidelines for the management of pemphigus vulgaris","volume":"149","author":"Harman","year":"2003","journal-title":"Br J Dermatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1016\/j.jid.2017.05.032","article-title":"Pivotal role of lesional and perilesional T\/B lymphocytes in pemphigus pathogenesis","volume":"137","author":"Yuan","year":"2017","journal-title":"J Invest Dermatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa2028564","article-title":"Rituximab versus mycophenolate mofetil in patients with pemphigus vulgaris","volume":"384","author":"Werth","year":"2021","journal-title":"N Engl J Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1111\/jdv.16752","article-title":"Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV)","volume":"34","author":"Joly","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1007\/s12325-016-0343-4","article-title":"Management of pemphigus vulgaris","volume":"33","author":"Cholera","year":"2016","journal-title":"Adv Ther."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1093\/aje\/kws375","article-title":"Use of azathioprine and the risk of cancer in inflammatory bowel disease","volume":"177","author":"Pasternak","year":"2013","journal-title":"Am J Epidemiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1046\/j.1365-2036.2002.01297.x","article-title":"Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine","volume":"16","author":"Fraser","year":"2002","journal-title":"Aliment Pharmacol Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1136\/bmj.2.6146.1190","article-title":"Azathioprine plus prednisone in treatment of pemphigoid","volume":"2","author":"Burton","year":"1978","journal-title":"Br Med J."},{"key":"B14","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00404-011-1859-0","article-title":"Successful pregnancy after cyclophosphamide therapy for lupus nephritis","volume":"283","author":"Lannes","year":"2011","journal-title":"Arch Gynecol Obstet."},{"key":"B15","doi-asserted-by":"publisher","first-page":"521","DOI":"10.2147\/CCID.S75908","article-title":"Management of pemphigus vulgaris: challenges and solutions","volume":"8","author":"Gregoriou","year":"2015","journal-title":"Clin Cosmet Investig Dermatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/j.1365-2133.2005.06651.x","article-title":"Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus","volume":"153","author":"Arin","year":"2005","journal-title":"Br J Dermatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1001\/archdermatol.2012.1522","article-title":"Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients","volume":"148","author":"Lunardon","year":"2012","journal-title":"Arch Dermatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2850","DOI":"10.1038\/jid.2008.172","article-title":"Rituximab exerts a dual effect in pemphigus vulgaris","volume":"128","author":"Eming","year":"2008","journal-title":"J Invest Dermatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/1523-1747.ep12613469","article-title":"Pemphigus IgG, but not bullous pemphigoid IgG, causes a transient increase in intracellular calcium and inositol 1,4,5-triphosphate in DJM-1 cells, a squamous cell carcinoma line","volume":"104","author":"Seishima","year":"1995","journal-title":"J Invest Dermatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1001\/archderm.134.8.971","article-title":"The pathophysiological significance of nondesmoglein targets of pemphigus autoimmunity","volume":"134","author":"Esaki","year":"1998","journal-title":"Arch Dermatol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/1523-1747.ep12319948","article-title":"Pharmacologic evidence for involvement of phospholipase C in pemphigus IgG-induced inositol 1,4,5-trisphosphate generation, intracellular calcium increase, and plasminogen activator secretion in DJM-1 cells, a squamous cell carcinoma line","volume":"105","author":"Esaki","year":"1995","journal-title":"J Invest Dermatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1111\/1523-1747.ep12289726","article-title":"Pemphigus IgG activates and translocates protein kinase C from the cytosol to the particulate\/cytoskeleton fractions in human keratinocytes","volume":"108","author":"Osada","year":"1997","journal-title":"J Investig Dermatol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1083\/jcb.153.4.823","article-title":"A central role for the armadillo protein plakoglobin in the autoimmune disease pemphigus vulgaris","volume":"153","author":"Reto Caldelari","year":"2001","journal-title":"J Cell Biol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1084\/jem.177.3.679","article-title":"B lymphocytes in vivo fail to prime naive T cells but can stimulate antigen-experienced T lymphocytes","volume":"177","author":"Ronchese","year":"1993","journal-title":"J Exp Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"622","DOI":"10.3389\/fimmu.2018.00622","article-title":"B cell modulation strategies in autoimmune diseases: new concepts","volume":"9","author":"Musette","year":"2018","journal-title":"Front Immunol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.jaci.2020.03.036","article-title":"Targeting inducible costimulator expressed on CXCR5(+)PD-1(+) TH cells suppresses the progression of pemphigus vulgaris","volume":"146","author":"Kim","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1016\/j.jaci.2020.11.008","article-title":"Immunophenotyping in pemphigus reveals a TH17\/TFH17 cell-dominated immune response promoting desmoglein1\/3-specific autoantibody production","volume":"147","author":"Holstein","year":"2021","journal-title":"J Allergy Clin Immunol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"3677","DOI":"10.1172\/JCI57379","article-title":"Desmoglein 3-specific CD4+ T cells induce pemphigus vulgaris and interface dermatitis in mice","volume":"121","author":"Takahashi","year":"2011","journal-title":"J Clin Invest."},{"key":"B29","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/intimm\/dxr020","article-title":"Antigen-independent development of Foxp3+ regulatory T cells suppressing autoantibody production in experimental pemphigus vulgaris","volume":"23","author":"Yokoyama","year":"2011","journal-title":"Int Immunol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1002\/1521-4141(200203)32:3<627::AID-IMMU627>3.0.CO;2-1","article-title":"Pathogenic autoantibody production requires loss of tolerance against desmoglein 3 in both T and B cells in experimental pemphigus vulgaris","volume":"32","author":"Tsunoda","year":"2002","journal-title":"Eur J Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"247426","DOI":"10.1155\/2015\/247426","article-title":"Effect of TACI signaling on humoral immunity and autoimmune diseases","volume":"2015","author":"Zhang","year":"2015","journal-title":"J Immunol Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMra052723","article-title":"The many roles of chemokines and chemokine receptors in inflammation","volume":"354","author":"Charo","year":"2006","journal-title":"N Engl J Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S1474-4422(08)70192-3","article-title":"B cells and multiple sclerosis","volume":"7","author":"Franciotta","year":"2008","journal-title":"Lancet Neurol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"iii34","DOI":"10.1136\/ard.2006.058412","article-title":"The BLyS\/BAFF family of ligands and receptors: key targets in the therapy and understanding of autoimmunity","volume":"65","author":"Cancro","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"B35","first-page":"1927","article-title":"Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study","volume":"92","author":"Coiffier","year":"1998","journal-title":"Blood."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"French study group on autoimmune bullous skin, First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet."},{"key":"B37","doi-asserted-by":"publisher","first-page":"175ra30","DOI":"10.1126\/scitranslmed.3005166","article-title":"Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response","volume":"5","author":"Colliou","year":"2013","journal-title":"Sci Transl Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.coph.2019.01.001","article-title":"Pharmacological advances in pemphigus","volume":"46","author":"Temel","year":"2019","journal-title":"Curr Opin Pharmacol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1111\/jdv.12678","article-title":"An assessment of treatment history and its association with clinical outcomes and relapse in 155 pemphigus patients with response to a single cycle of rituximab","volume":"29","author":"Amber","year":"2015","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"928","DOI":"10.2340\/00015555-2116","article-title":"Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens","volume":"95","author":"Wang","year":"2015","journal-title":"Acta Derm Venereol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1038\/jid.2014.291","article-title":"Persistence of anti-desmoglein 3 IgG(+) B-cell clones in pemphigus patients over years","volume":"135","author":"Hammers","year":"2015","journal-title":"J Invest Dermatol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"17026","DOI":"10.1038\/nrdp.2017.26","article-title":"Pemphigus","volume":"3","author":"Kasperkiewicz","year":"2017","journal-title":"Nat Rev Dis Primers."},{"key":"B43","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1586\/eci.11.22","article-title":"Relevance of rituximab therapy in pemphigus vulgaris: analysis of current data and the immunologic basis for its observed responses","volume":"7","author":"Feldman","year":"2011","journal-title":"Expert Rev Clin Immunol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4161\/mabs.22771","article-title":"Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties","volume":"5","author":"Klein","year":"2013","journal-title":"MAbs."},{"key":"B45","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.jaad.2015.11.008","article-title":"Future therapies for pemphigus vulgaris: Rituximab and beyond","volume":"74","author":"Huang","year":"2016","journal-title":"J Am Acad Dermatol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1001\/jamadermatol.2014.1939","article-title":"Subcutaneous veltuzumab, a humanized anti-CD20 antibody, in the treatment of refractory pemphigus vulgaris","volume":"150","author":"Ellebrecht","year":"2014","journal-title":"JAMA Dermatol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1517\/13543780902832679","article-title":"Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders","volume":"18","author":"Castillo","year":"2009","journal-title":"Expert Opin Investig Drugs."},{"key":"B48","doi-asserted-by":"publisher","first-page":"978","DOI":"10.3389\/fimmu.2019.00978","article-title":"Current clinical trials in pemphigus and pemphigoid","volume":"10","author":"Izumi","year":"2019","journal-title":"Front Immunol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N Engl J Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N Engl J Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"983","DOI":"10.3109\/10428191003717746","article-title":"The future of CD20 monoclonal antibody therapy in B-cell malignancies","volume":"51","author":"Czuczman","year":"2010","journal-title":"Leuk Lymphoma."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.3389\/fimmu.2019.01418","article-title":"Pemphigus: current and future therapeutic strategies","volume":"10","author":"Didona","year":"2019","journal-title":"Front Immunol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.3389\/fimmu.2017.01454","article-title":"Bruton's tyrosine kinase: an emerging key player in innate immunity","volume":"8","author":"Weber","year":"2017","journal-title":"Front Immunol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1111\/bcp.13351","article-title":"A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers","volume":"83","author":"Smith","year":"2017","journal-title":"Br J Clin Pharmacol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/bjd.20431","article-title":"Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study","volume":"185","author":"Murrell","year":"2021","journal-title":"Br J Dermatol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jdermsci.2021.07.002","article-title":"A multicenter, open-label, uncontrolled, single-arm phase 2 study of tirabrutinib, an oral Bruton's tyrosine kinase inhibitor, in pemphigus","volume":"103","author":"Yamagami","year":"2021","journal-title":"J Dermatol Sci."},{"key":"B58","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/jdv.12772","article-title":"Pemphigus. S2 Guideline for diagnosis and treatment\u2013guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV)","volume":"29","author":"Hertl","year":"2015","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/S0140-6736(97)09278-7","article-title":"Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients","volume":"350","author":"Nashan","year":"1997","journal-title":"CHIB 201 International Study Group Lancet."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1111\/j.1365-2133.2004.05977.x","article-title":"A novel therapeutic option in pemphigus vulgaris: humanized monoclonal anti-CD25 antibody","volume":"150","author":"Renkl","year":"2004","journal-title":"Br J Dermatol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/sj.jid.5700016","article-title":"Tolerance induction by the blockade of CD40\/CD154 interaction in pemphigus vulgaris mouse model","volume":"126","author":"Aoki-Ota","year":"2006","journal-title":"J Invest Dermatol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"757","DOI":"10.2147\/TCRM.S142471","article-title":"Emerging treatment options for the management of pemphigus vulgaris","volume":"14","author":"Kridin","year":"2018","journal-title":"Ther Clin Risk Manag."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1074\/jbc.M110.172874","article-title":"p38 MAPK activation is downstream of the loss of intercellular adhesion in pemphigus vulgaris","volume":"286","author":"Mao","year":"2011","journal-title":"J Biol Chem."},{"key":"B64","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1046\/j.1523-1747.2000.00835.x","article-title":"In vitro and in vivo expression of interleukin-1alpha and tumor necrosis factor-alpha mRNA in pemphigus vulgaris: interleukin-1alpha and tumor necrosis factor-alpha are involved in acantholysis","volume":"114","author":"Feliciani","year":"2000","journal-title":"J Invest Dermatol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.intimp.2017.10.027","article-title":"Current and future treatment options for pemphigus: Is it time to move towards more effective treatments?","volume":"53","author":"Tavakolpour","year":"2017","journal-title":"Int Immunopharmacol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1111\/j.1365-2133.2005.06744.x","article-title":"Rapid control of therapy-refractory pemphigus vulgaris by treatment with the tumour necrosis factor-alpha inhibitor infliximab","volume":"153","author":"Jacobi","year":"2005","journal-title":"Br J Dermatol."},{"key":"B67","first-page":"245","article-title":"Treatment of recalcitrant pemphigus vulgaris with the tumor necrosis factor alpha antagonist etanercept","volume":"74","author":"Berookhim","year":"2004","journal-title":"Cutis."},{"key":"B68","doi-asserted-by":"publisher","first-page":"e196","DOI":"10.1016\/j.jaad.2011.05.029","article-title":"Infliximab therapy failure in two patients with pemphigus vulgaris","volume":"67","author":"Garcia-Rabasco","year":"2012","journal-title":"J Am Acad Dermatol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1007\/s12026-013-8411-1","article-title":"Refractory pemphigus foliaceus and Behcet's disease successfully treated with tocilizumab","volume":"56","author":"Caso","year":"2013","journal-title":"Immunol Res."},{"key":"B70","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.autrev.2009.01.012","article-title":"Interleukin-6 as a key player in systemic inflammation and joint destruction","volume":"8","author":"Fonseca","year":"2009","journal-title":"Autoimmun Rev."},{"key":"B71","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.cyto.2015.09.017","article-title":"Interleukin 4 inhibition as a potential therapeutic in pemphigus","volume":"77","author":"Tavakolpour","year":"2016","journal-title":"Cytokine."},{"key":"B72","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/dth.12327","article-title":"Dupilumab: a revolutionary emerging drug in atopic dermatitis and its possible role in pemphigus","volume":"29","author":"Tavakolpour","year":"2016","journal-title":"Dermatol Ther."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-3083.2010.02470.x","article-title":"Functional and clinical aspects of the B-cell-activating factor (BAFF): a narrative review","volume":"73","author":"Lied","year":"2011","journal-title":"Scand J Immunol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nri844","article-title":"BAFF a fundamental survival factor for B cells","volume":"2","author":"Mackay","year":"2002","journal-title":"Nat Rev Immunol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1172\/JCI18025","article-title":"BAFF selectively enhances the survival of plasmablasts generated from human memory B cells","volume":"112","author":"Avery","year":"2003","journal-title":"J Clin Invest."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1084\/jem.188.6.1185","article-title":"APRIL a new ligand of the tumor necrosis factor family, stimulates tumor cell growth","volume":"188","author":"Hahne","year":"1998","journal-title":"J Exp Med."},{"key":"B77","doi-asserted-by":"publisher","first-page":"370","DOI":"10.3389\/fimmu.2018.00370","article-title":"Soluble fas ligand is essential for blister formation in pemphigus","volume":"9","author":"Lotti","year":"2018","journal-title":"Front Immunol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.det.2018.12.003","article-title":"Treatment update of autoimmune blistering diseases","volume":"37","author":"Kridin","year":"2019","journal-title":"Dermatol Clin."},{"key":"B79","doi-asserted-by":"publisher","first-page":"408","DOI":"10.3389\/fimmu.2014.00408","article-title":"The role of FcRn in antigen presentation","volume":"5","author":"Baker","year":"2014","journal-title":"Front Immunol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1172\/JCI24394","article-title":"Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases","volume":"115","author":"Li","year":"2005","journal-title":"J Clin Invest."},{"key":"B81","doi-asserted-by":"publisher","first-page":"176","DOI":"10.3389\/fimmu.2015.00176","article-title":"Fully human monoclonal antibody inhibitors of the neonatal fc receptor reduce circulating IgG in non-human primates","volume":"6","author":"Nixon","year":"2015","journal-title":"Front Immunol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1038\/nbt1143","article-title":"Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels","volume":"23","author":"Vaccaro","year":"2005","journal-title":"Nat Biotechnol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/bjd.20782","article-title":"Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open-label feasibility trial","volume":"186","author":"Goebeler","year":"2022","journal-title":"Br J Dermatol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science."},{"key":"B85","doi-asserted-by":"publisher","first-page":"6317","DOI":"10.1172\/JCI138416","article-title":"Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris","volume":"130","author":"Lee","year":"2020","journal-title":"J Clin Invest"},{"key":"B86","doi-asserted-by":"publisher","first-page":"100014","DOI":"10.1016\/j.jtauto.2019.100014","article-title":"The pathogenesis of bullous skin diseases","volume":"2","author":"Yang","year":"2019","journal-title":"J Transl Autoimmun"},{"key":"B87","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.clim.2009.06.001","article-title":"First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells","volume":"133","author":"Trzonkowski","year":"2009","journal-title":"Clin Immunol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"315ra189","DOI":"10.1126\/scitranslmed.aad4134","article-title":"Type 1 diabetes immunotherapy using polyclonal regulatory T cells","volume":"7","author":"Bluestone","year":"2015","journal-title":"Sci Transl Med"},{"key":"B89","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1038\/sj.bmt.1704679","article-title":"High-dose immune suppression and autologous hematopoietic stem cell transplantation in refractory pemphigus foliaceus","volume":"34","author":"Oyama","year":"2004","journal-title":"Bone Marrow Transplant."},{"key":"B90","first-page":"785","article-title":"Pemphigus vulgaris treated with allogeneic hematopoietic stem cell transplantation following non-myeloablative conditioning","volume":"14","author":"Suslova","year":"2010","journal-title":"Eur Rev Med Pharmacol Sci."},{"key":"B91","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/ijd.13461","article-title":"Application of autologous hematopoietic stem cell transplantation for pemphigus","volume":"56","author":"Wang","year":"2017","journal-title":"Int J Dermatol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4103\/0019-5154.92667","article-title":"Allogenic hematopoietic stem cell transplantation in pemphigus vulgaris: a single-center experience","volume":"57","author":"Vanikar","year":"2012","journal-title":"Indian J Dermatol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"23778","DOI":"10.1074\/jbc.M501365200","article-title":"Desmosome signaling. Inhibition of p38MAPK prevents pemphigus vulgaris IgG-induced cytoskeleton reorganization","volume":"280","author":"Berkowitz","year":"2005","journal-title":"J Biol Chem."},{"key":"B94","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.jid.2021.04.040","article-title":"Pemphigus and pemphigoid: from disease mechanisms to druggable pathways","volume":"142","author":"Ellebrecht","year":"2022","journal-title":"J Invest Dermatol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"e2022037","DOI":"10.5826\/dpc.1201a37","article-title":"Pemphigus vulgaris: present and future therapeutic strategies","volume":"12","author":"Didona","year":"2022","journal-title":"Dermatol Pract Concept."},{"key":"B96","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s12016-021-08882-1","article-title":"Comparison of guidelines for management of pemphigus: a review of systemic corticosteroids, rituximab, and other immunosuppressive therapies","volume":"61","author":"Zhao","year":"2021","journal-title":"Clin Rev Allergy Immunol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/S0140-6736(19)31778-7","article-title":"Pemphigus","volume":"394","author":"Schmidt","year":"2019","journal-title":"Lancet."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.901239\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T03:31:55Z","timestamp":1655263915000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.901239\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,15]]},"references-count":97,"alternative-id":["10.3389\/fmed.2022.901239"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.901239","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,15]]},"article-number":"901239"}}